RU2008131509A - PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES - Google Patents
PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES Download PDFInfo
- Publication number
- RU2008131509A RU2008131509A RU2008131509/15A RU2008131509A RU2008131509A RU 2008131509 A RU2008131509 A RU 2008131509A RU 2008131509/15 A RU2008131509/15 A RU 2008131509/15A RU 2008131509 A RU2008131509 A RU 2008131509A RU 2008131509 A RU2008131509 A RU 2008131509A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- interferon beta
- effective amount
- composition according
- dalargin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 17
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 claims abstract 11
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 claims abstract 11
- 108010005714 Interferon beta-1b Proteins 0.000 claims abstract 10
- 239000003085 diluting agent Substances 0.000 claims abstract 10
- 229960003161 interferon beta-1b Drugs 0.000 claims abstract 10
- 239000003937 drug carrier Substances 0.000 claims abstract 8
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract 4
- 108090000467 Interferon-beta Proteins 0.000 claims abstract 4
- 102000003996 Interferon-beta Human genes 0.000 claims abstract 4
- 229960001388 interferon-beta Drugs 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000008215 water for injection Substances 0.000 claims abstract 3
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract 2
- 230000000840 anti-viral effect Effects 0.000 claims abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Фармацевтическая композиция для лечения демиелинизирующих заболеваний, содержащая эффективное количество интерферона бета, его аналога, производного или конъюгата, отличающаяся тем, что дополнительно содержит эффективное количество даларгина и, при необходимости, фармацевтически приемлемый наполнитель или разбавитель. ! 2. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве интерферона бета она содержит интерферон бета-1b. ! 3. Фармацевтическая композиция по п.2, отличающаяся тем, что эффективное количество интерферона бета-1b составляет от 3 до 150 млн МЕ, а эффективное количество даларгина составляет от 0,1 до 5,0 мг на единичную дозу. ! 4. Фармацевтическая композиция по п.3, отличающаяся тем, что эффективное количество интерферона бета-1b составляет от 5 до 20 млн МЕ, а эффективное количество даларгина составляет от 0,5 до 1,5 мг на единичную дозу. ! 5. Фармацевтическая композиция по п.4, отличающаяся тем, что содержит следующее соотношение компонентов в расчете на единичную дозу: ! интерферона бета-1b9,6 млн МЕдаларгин1,0 мгфармацевтически приемлемый носитель или разбавитель1,0 мл ! 6. Фармацевтическая композиция по п.2, отличающаяся тем, что содержит следующее соотношение компонентов, мг, в расчете на единичную дозу: ! интерферона бета-1b0,3даларгин1,0фармацевтически приемлемый носитель или разбавитель1000,0 ! 7. Фармацевтическая композиция по любому из пп.1-5, отличающаяся тем, что фармацевтически приемлемым носителем или разбавителем является вода для инъекций. ! 8. Фармацевтическая композиция по п.1 или 2, отличающаяся тем, что она дополнительно оказывает иммуномодулирующее, противовирусное и антипролиферативное д�1. A pharmaceutical composition for the treatment of demyelinating diseases, containing an effective amount of interferon beta, its analogue, derivative or conjugate, characterized in that it further comprises an effective amount of dalargin and, if necessary, a pharmaceutically acceptable excipient or diluent. ! 2. The pharmaceutical composition according to claim 1, characterized in that as interferon beta it contains interferon beta-1b. ! 3. The pharmaceutical composition according to claim 2, characterized in that the effective amount of interferon beta-1b is from 3 to 150 million IU, and the effective amount of dalargin is from 0.1 to 5.0 mg per unit dose. ! 4. The pharmaceutical composition according to claim 3, characterized in that the effective amount of interferon beta-1b is from 5 to 20 million IU, and the effective amount of dalargin is from 0.5 to 1.5 mg per unit dose. ! 5. The pharmaceutical composition according to claim 4, characterized in that it contains the following ratio of components per unit dose:! interferon beta-1b9.6 million MEDalargin 1.0 mg pharmaceutically acceptable carrier or diluent 1.0 ml! 6. The pharmaceutical composition according to claim 2, characterized in that it contains the following ratio of components, mg, per unit dose:! interferon beta-1b0.3 dalargin 1.0 pharmaceutically acceptable carrier or diluent 1000.0! 7. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that the pharmaceutically acceptable carrier or diluent is water for injection. ! 8. The pharmaceutical composition according to claim 1 or 2, characterized in that it additionally provides immunomodulating, antiviral and antiproliferative d�
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008131509/15A RU2008131509A (en) | 2008-07-31 | 2008-07-31 | PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008131509/15A RU2008131509A (en) | 2008-07-31 | 2008-07-31 | PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008131509A true RU2008131509A (en) | 2010-02-10 |
Family
ID=42123376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008131509/15A RU2008131509A (en) | 2008-07-31 | 2008-07-31 | PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2008131509A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556377A1 (en) | 2018-04-18 | 2019-10-23 | PVP Labs PTE. Ltd. | Antiviral immunotropic agent for the treatment of acute respiratory viral infections |
| EP3622964A1 (en) | 2018-09-12 | 2020-03-18 | PVP Labs PTE. Ltd. | Agent for the treatment of skin wounds or burns |
-
2008
- 2008-07-31 RU RU2008131509/15A patent/RU2008131509A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556377A1 (en) | 2018-04-18 | 2019-10-23 | PVP Labs PTE. Ltd. | Antiviral immunotropic agent for the treatment of acute respiratory viral infections |
| EP3622964A1 (en) | 2018-09-12 | 2020-03-18 | PVP Labs PTE. Ltd. | Agent for the treatment of skin wounds or burns |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2355700C9 (en) | Novel peptides as inhibitors of hepatitis c virus ns3 serine protease | |
| RU2009126616A (en) | POWDER VALGANTSIKLOVIR | |
| EA200602130A1 (en) | SUBSTITUTED ARYLACYLTIOMETRIC AND RELATED COMPOUNDS; VIRUS REPLICATION INHIBITORS | |
| HRP20110169T1 (en) | USE OF [D-MEAL] 3- [ETVAL] 4-CYCLOSPORINE FOR THE TREATMENT OF HEPATITIS C INFECTIONS | |
| RU2016122609A (en) | COMPOSITIONS OF AZAINDOL COMPOUNDS | |
| NO20076219L (en) | Pharmaceutical formulation with apomorphine for buccal administration | |
| RU2012109392A (en) | PHARMACEUTICAL COMPOSITION FOR REDUCING PAIN | |
| RU2010129824A (en) | NEW functionally active, highly purified, stable Alpha interferon conjugate with polyethylene glycol, represented by one of positional isomers of PEG-IFN-NAH with reduced immunogenicity, with a prolonged biological effect are suitable for medical applications, and immunobiological agent based on ITS | |
| RU2020107416A (en) | A COMBINATION CONTAINING PALBOCYCLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] -8,9-DIHYDRO-7H-BENZO [7 ] ANNULENE-2-CARBONIC ACID AND ITS USE FOR TREATMENT OF CANCER | |
| RU2008131509A (en) | PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF DIMIELINIZING DISEASES | |
| WO2011111070A2 (en) | Novel injectable combination | |
| ES2078838A1 (en) | PROCEDURE FOR PREPARING A CLOZAPINE BASED COMPOSITION. | |
| RU2010129409A (en) | METHOD FOR TREATING RABBIT PSOROPTOSIS AND CARNIVOR ANIMAL OTODEKTOSIS | |
| RU2008113615A (en) | METHOD FOR TREATING INFECTIONS CAUSED BY FIRST AND SECOND TYPES SIMPLE VIRUS, CYTOMEGALOVIRUS, EPSTEIN-BARR VIRUS | |
| RU2010134748A (en) | DRUG FOR CORRECTION OF EXCHANGE PROCESSES AND IMPROVEMENT OF NATURAL RESISTANCE OF ANIMAL ORGANISM | |
| MX2021012782A (en) | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations. | |
| RU2013124416A (en) | DIINDOLYLMETHANE MEDICINAL PRODUCT AND ITS APPLICATION FOR TREATMENT OF INFLUENZA AND RESPIRATORY VIRAL INFECTIONS | |
| RU2015114709A (en) | STABLE INJECTION COMPOSITION CONTAINING DICLOFENAC AND THIOCOLCHICOSIDE | |
| RU2015111491A (en) | COMBINATION OF THE MACROCYCLIC HCV PROTEASE INHIBITOR, HCV NON-NUCLEOSIDE INHIBITOR AND RITONAVIR | |
| KR20070012522A (en) | Treatment and prevention of respiratory viral infections with immunomodulatory compounds | |
| RU2008131510A (en) | PHARMACEUTICAL COMPOSITION AND KIT FOR TREATMENT OF TUMOR DISEASES | |
| US7288525B2 (en) | Method for lowering serum homocysteine | |
| RU2013148539A (en) | ALISPORIVIR FOR TREATMENT OF HEPATITIS C VIRUS INFECTION | |
| RU2005104747A (en) | THE DRUG FOR THE TREATMENT OF POST-UNIVERSAL PURULAR-CATARAL ENDOMETRITIS AND MASTITIS IN COWS AND METHODS OF ITS APPLICATION | |
| RU2007140808A (en) | PHARMACEUTICAL INJECTION PRODUCT BASED ON A LOW-MOLECULAR INTERFERON INDUCTOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100623 |